Picard Medical, Inc. enters its September 10 earnings finalization with a consensus revenue estimate of $1.55 million and an expected EPS loss of $1.50, as shares trade near $4.70 against a bullish $195.00 analyst target.
Investors are primarily focused on the clinical development and electromechanical architecture of the next-generation Emperor Total Artificial Heart (TAH) platform.
Preliminary reports suggest the company achieved a significant top-line beat with actual revenue of $2.95 million, driven by strong U.S. sales of the current SynCardia model. Management continues to work through NYSE American listing requirements following a 1-for-50 reverse stock split and a notable shift toward positive gross profitability.